Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 20/20 | 1.00 |
| ▸ | P2RX2 | Q9UBL9 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30092086 | 1.00 | P2RX3 (1.00) | P2RX3P2RX2CYP2C9 | |
| SCHEMBL23111474 | 1.00 | P2RX3 (1.00) | P2RX3P2RX2CYP2C9 | |
| SCHEMBL17823881 | 0.94 | P2RX3 (1.00) | P2RX3P2RX2CYP2C9 | |
| SCHEMBL30277267 | 0.94 | P2RX3 (1.00) | P2RX3P2RX2CYP2C9 | |
| SCHEMBL19950292 | 0.94 | P2RX3 (1.00) | P2RX3P2RX2CYP2C9 | |
| SCHEMBL30092165 | 0.87 | P2RX3 (1.00) | P2RX3P2RX2CYP2C9 | |
| SCHEMBL17824101 | 0.87 | P2RX3 (1.00) | P2RX3P2RX2CYP2C9 | |
| SCHEMBL21875549 | 0.87 | P2RX3 (1.00) | P2RX3P2RX2CYP2C9 | |
| SCHEMBL28968120 | 0.87 | P2RX3 (0.86) | P2RX3P2RX2CYP2C9 | |
| SCHEMBL28968121 | 0.87 | P2RX3 (0.86) | P2RX3P2RX2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | US | disclosed |
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | US | disclosed |
| CN-110256418-B | 1, 3-thiazol-2-yl substituted benzamides | 拜耳公司 | 2023-01-20 | — | — | CN | disclosed |
| EP-3587417-B9 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2022-03-30 | — | — | EP | disclosed |
| EP-3587417-B1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2022-01-05 | — | — | EP | disclosed |
| US-11142523-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-12 | — | — | US | disclosed |
| US-11142523-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-12 | — | — | US | disclosed |
| US-20210220358-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-07-22 | — | — | US | disclosed |
| US-20210220357-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-07-22 | — | — | US | disclosed |
| EP-3230281-B1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2021-05-26 | — | — | EP | disclosed |
| US-20180118731-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | US | disclosed |
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-03-15 | — | — | US | disclosed |
| EP-3230281-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | Bayer Aktiengesellschaft (DE) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016091776-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016091776-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | P2RX3 578/4885P2RX2 541/4885CYP2C9 1392/4885 |
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | P2RX3 578/4885P2RX2 541/4885CYP2C9 1392/4885 |
| US-20180118731-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | P2RX3 578/4885P2RX2 541/4885CYP2C9 1392/4885 |
| US-20210220357-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | BRS3, P2RX3, ADRB3 | P2RX3 2/4885P2RX2 10/4885CYP2C9 2749/4885 |
| US-20210220358-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | HRH2, HRH1, TRPA1 | P2RX3 262/4885P2RX2 399/4885CYP2C9 3679/4885 |
| US-11142523-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | P2RX3 578/4885P2RX2 541/4885CYP2C9 1392/4885 |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | P2RX3 578/4885P2RX2 541/4885CYP2C9 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.